MHRA grants CTA for the POLB 001 TOPICAL trial

AI SummaryClose X

Poolbeg Pharma plc has received Clinical Trial Authorisation from the MHRA for its POLB 001 TOPICAL trial, which is on track to deliver interim data this summer, and independent research indicates a multi-billion-dollar peak sales potential in the United States for POLB 001, a potential preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome. The trial will involve approximately 30 patients and has expanded to six UK sites, with patient screening commencing shortly. The payer research, covering around 75 million lives, highlights POLB 001's value proposition in reducing hospital costs and enabling a shift in care settings, reinforcing confidence in its market opportunity and appeal to potential partners.

Disclaimer*

UK 100

Latest directors dealings